These observations suggest that activation of GPRC6A may provide a method to treat metabolic syndrome (MetS), type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD). Here, GPRC6A is linked to metabolic dysfunction-associated steatotic liver disease.